Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Shaking Off the (Brain) Rust

04.11.2004


Researchers at the Technion-Israel Institute of Technology have developed three drugs to remove excess iron from the brains of patients with neurodegenerative diseases. The presence of too much iron in the brain is a hallmark of such diseases. The drugs, VK-28, HLA-20 and M30, mop up the iron before it can trigger a "brain rust" chemical reaction where highly active oxygen particles destroy brain cells.

Professor Moussa Youdim of the Faculty of Medicine and his colleagues – Prof. Avraham Warshawsky (now deceased), Prof. Mati Fridkin and Ph.D. student Hailin Zheng from China – have received U.S. and worldwide patents on VK-28, HLA-20 and M30. Youdim says the three drugs could treat and perhaps prevent a range of diseases including Parkinson’s, Alzheimer’s, Huntington’s and amyotrophic lateral sclerosis (ALS).

Unlike other drugs currently used against these disorders – which attempt to replace the functions lost by dying neurons – these drugs halt the neuron destruction itself. Normally, iron is a helpful partner in the body’s metabolism, shuttling electrons between molecules in chemical reactions that break down fats, carbohydrates and proteins, and provide energy to cells. Because iron is so reactive, the body usually keeps tight control over the amount and activity of iron circulating in the brain and other organs.



When these control mechanisms fail, however, too much "free" iron can participate in rust-like reactions that produce damaging byproducts such as oxygen free radicals. These highly active particles hurtle themselves at cells with destructive force, collapsing and eventually killing them. The deadly bombardment might explain why neurons die off in the iron-rich brain tissue of Parkinson’s and Alzheimer’s patients, Youdim says.

Youdim and his former student, Dr. Dorit Ben Shachar, were the first to suggest that iron chelators could prevent the neurotoxicity of iron in an animal model of Parkinson’s disease with Desferal, a well-known iron chelator. Iron chelators are small molecules that bind to excess iron and prevent it from participating in chemical reactions that could damage neurons and other cells.

But they discovered that Desferal needed to be directly injected into the brain, leading to the new VK-28, which can cross into the brain via the bloodstream. The other two drugs – HLA-20 and M30 – are combination drugs. They increase Dopamine levels and remove excess iron that could cause further damage to the neurons that transmit dopamine. "Drugs with multiple actions may be more effective in controlling and treating neurodegenerative disorders," he explains.

The work of Youdim and his colleagues appears in the November 2004 Nature Review Neuroscience. The have also published several other papers on their iron chelator research, including articles in the Annals of the New York Academy of Sciences (January 2004) and Neuropharmacology (January 2004) earlier this year. They will also be published in Trends in Pharmacological Sciences later this year. The researchers are now in negotiations with several American, British and Israeli companies for development of these drugs through Varinel Inc.

Youdim also discovered and co-developed Rasagiline, a drug that boosts levels of a brain chemical called dopamine that is normally depleted in Parkinson’s patients; and Ladostigil, which boosts levels of acetylcholine in Alzheimer’s patients. Rasagiline has received a letter of approval from the FDA, while Ladostigil is currently in the clinical trials phase.

The Technion-Israel Institute of Technology is Israel’s leading science and technology university and home to the country’s only winners of the Nobel Prize in science. It commands a worldwide reputation for its pioneering work in computer science, biotechnology, water-resource management, materials engineering, aerospace and medicine. The majority of the founders and managers of Israel’s high-tech companies are alumni. Based in New York City, the American Technion Society is the leading American organization supporting higher education in Israel, with more than 20,000 supporters and 19 offices around the country.

| newswise
Further information:
http://www.ats.org

More articles from Health and Medicine:

nachricht Purdue cancer identity technology makes it easier to find a tumor's 'address'
16.11.2018 | Purdue University

nachricht Microgel powder fights infection and helps wounds heal
14.11.2018 | Michigan Technological University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: UNH scientists help provide first-ever views of elusive energy explosion

Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.

Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...

Im Focus: A Chip with Blood Vessels

Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.

Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

Im Focus: Research icebreaker Polarstern begins the Antarctic season

What does it look like below the ice shelf of the calved massive iceberg A68?

On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.

Im Focus: Penn engineers develop ultrathin, ultralight 'nanocardboard'

When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure

Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

European Space Talks: Weltraumschrott – eine Gefahr für die Gesellschaft?

23.10.2018 | Event News

 
Latest News

Purdue cancer identity technology makes it easier to find a tumor's 'address'

16.11.2018 | Health and Medicine

Good preparation is half the digestion

16.11.2018 | Life Sciences

Microscope measures muscle weakness

16.11.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>